Young David

Pres. Research & Development

Young David has filed 8 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2026. 8 of those filings fall inside the rolling window. Most recent filing: Jul 1, 2026.

On the most recent filing, Young David is listed as Pres. Research & Development at Processa Pharmaceuticals, Inc. Inside the rolling window, Young David reported 7 open-market purchases totaling $32K in PCSA and no open-market sales. The largest disclosed transaction in the window is a purchase of 2,531 PCSA shares on Jun 30, 2026, worth $5K.

Companies traded

Other insiders at PCSA

Insider Buying

$32K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
PCSAPurchase$5KJul 1SEC ↗
PCSAPurchase$5KJun 16SEC ↗
PCSAPurchase$5KJun 1SEC ↗
PCSAPurchase$5KMay 19SEC ↗
PCSAPurchase$5KMay 1SEC ↗
PCSAPurchase$5KApr 17SEC ↗
PCSAPurchase$5KApr 1SEC ↗

Frequently asked questions

How many SEC Form 4 filings has Young David made?

Young David has filed 8 SEC Form 4 filings (8 transaction rows) across 1 company since 2026.

Which companies does Young David trade?

Young David has filed SEC Form 4 disclosures for 1 company, including PCSA.

When was Young David's most recent SEC Form 4 filing?

Young David's most recent SEC Form 4 filing on Tracefour is dated Jul 1, 2026.

What is Young David's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Young David is listed as Pres. Research & Development.

What is Young David's total buy and sell value in the current window?

Inside the rolling retention window, Young David bought $32K and sold $0 based on SEC Form 4 filings.

What was Young David's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 2,531 PCSA shares on 2026-06-30, worth $5K, per SEC Form 4 filings.